Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease : A Nationwide Cohort Study
© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation..
BACKGROUND AND AIMS: The COVID-19 risk and disease course in inflammatory bowel disease [IBD] patients remains uncertain. Therefore, we aimed to assess the clinical presentation, disease course, and outcomes of COVID-19 in IBD patients. Second, we determined COVID-19 incidences in IBD patients and compared this with the general population.
METHODS: We conducted a multicentre, nationwide IBD cohort study in The Netherlands and identified patients with COVID-19. First, we assessed the COVID-19 disease course and outcomes. Second, we compared COVID-19 incidences between our IBD study cohort and the general Dutch population.
RESULTS: We established an IBD cohort of 34 763 patients. COVID-19 was diagnosed in 100/34 763 patients [0.29%]; 20/100 of these patients [20%] had severe COVID-19 defined as admission to the intensive care unit, mechanical ventilation, and/or death. Hospitalisation occurred in 59/100 [59.0%] patients and 13/100 [13.0%] died. All patients who died had comorbidities and all but one were ≥65 years old. In line, we identified ≥1 comorbidity as an independent risk factor for hospitalisation (odds ratio [OR] 4.20, 95% confidence interval [CI] 1.58-11.17,; p = 0.004). Incidences of COVID-19 between the IBD study cohort and the general population were comparable (287.6 [95% CI 236.6-349.7] versus 333.0 [95% CI 329.3-336.7] per 100000 patients, respectively; p = 0.15).
CONCLUSIONS: Of 100 cases with IBD and COVID-19, 20% developed severe COVID-19, 59% were hospitalised and 13% died. A comparable COVID-19 risk was found between the IBD cohort [100/34 763 = 0.29%] and the general Dutch population. The presence of ≥1 comorbidities was an independent risk factor for hospitalisation due to COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Journal of Crohn's & colitis - 15(2021), 4 vom: 06. Apr., Seite 529-539 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Derikx, Lauranne A A P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Crohn’s disease |
|---|
| Anmerkungen: |
Date Completed 19.04.2021 Date Revised 07.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ecco-jcc/jjaa215 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316484652 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316484652 | ||
| 003 | DE-627 | ||
| 005 | 20231225161201.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ecco-jcc/jjaa215 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316484652 | ||
| 035 | |a (NLM)33079178 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Derikx, Lauranne A A P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease |b A Nationwide Cohort Study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2021 | ||
| 500 | |a Date Revised 07.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. | ||
| 520 | |a BACKGROUND AND AIMS: The COVID-19 risk and disease course in inflammatory bowel disease [IBD] patients remains uncertain. Therefore, we aimed to assess the clinical presentation, disease course, and outcomes of COVID-19 in IBD patients. Second, we determined COVID-19 incidences in IBD patients and compared this with the general population | ||
| 520 | |a METHODS: We conducted a multicentre, nationwide IBD cohort study in The Netherlands and identified patients with COVID-19. First, we assessed the COVID-19 disease course and outcomes. Second, we compared COVID-19 incidences between our IBD study cohort and the general Dutch population | ||
| 520 | |a RESULTS: We established an IBD cohort of 34 763 patients. COVID-19 was diagnosed in 100/34 763 patients [0.29%]; 20/100 of these patients [20%] had severe COVID-19 defined as admission to the intensive care unit, mechanical ventilation, and/or death. Hospitalisation occurred in 59/100 [59.0%] patients and 13/100 [13.0%] died. All patients who died had comorbidities and all but one were ≥65 years old. In line, we identified ≥1 comorbidity as an independent risk factor for hospitalisation (odds ratio [OR] 4.20, 95% confidence interval [CI] 1.58-11.17,; p = 0.004). Incidences of COVID-19 between the IBD study cohort and the general population were comparable (287.6 [95% CI 236.6-349.7] versus 333.0 [95% CI 329.3-336.7] per 100000 patients, respectively; p = 0.15) | ||
| 520 | |a CONCLUSIONS: Of 100 cases with IBD and COVID-19, 20% developed severe COVID-19, 59% were hospitalised and 13% died. A comparable COVID-19 risk was found between the IBD cohort [100/34 763 = 0.29%] and the general Dutch population. The presence of ≥1 comorbidities was an independent risk factor for hospitalisation due to COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Crohn’s disease | |
| 650 | 4 | |a Ulcerative colitis | |
| 650 | 4 | |a intensive care unit | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a severe COVID-19 | |
| 700 | 1 | |a Lantinga, Marten A |e verfasserin |4 aut | |
| 700 | 1 | |a de Jong, Dirk J |e verfasserin |4 aut | |
| 700 | 1 | |a van Dop, Willemijn A |e verfasserin |4 aut | |
| 700 | 1 | |a Creemers, Rob H |e verfasserin |4 aut | |
| 700 | 1 | |a Römkens, Tessa E H |e verfasserin |4 aut | |
| 700 | 1 | |a Jansen, Jeroen M |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmmod, Nofel |e verfasserin |4 aut | |
| 700 | 1 | |a West, Rachel L |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Adriaan C I T L |e verfasserin |4 aut | |
| 700 | 1 | |a Bodelier, Alexander G L |e verfasserin |4 aut | |
| 700 | 1 | |a Gorter, Moniek H P |e verfasserin |4 aut | |
| 700 | 1 | |a Boekema, Paul J |e verfasserin |4 aut | |
| 700 | 1 | |a Halet, Eric R C |e verfasserin |4 aut | |
| 700 | 1 | |a Horjus, Carmen S |e verfasserin |4 aut | |
| 700 | 1 | |a van Dijk, Maarten A |e verfasserin |4 aut | |
| 700 | 1 | |a Hirdes, Meike M C |e verfasserin |4 aut | |
| 700 | 1 | |a Epping Stippel, Ludger S M |e verfasserin |4 aut | |
| 700 | 1 | |a Jharap, Bindia |e verfasserin |4 aut | |
| 700 | 1 | |a Lutgens, Maurice W M D |e verfasserin |4 aut | |
| 700 | 1 | |a Russel, Maurice G |e verfasserin |4 aut | |
| 700 | 1 | |a Gilissen, Lennard P L |e verfasserin |4 aut | |
| 700 | 1 | |a Nauta, Sjoukje |e verfasserin |4 aut | |
| 700 | 1 | |a van Bodegraven, Adriaan A |e verfasserin |4 aut | |
| 700 | 1 | |a Hoentjen, Frank |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Crohn's & colitis |d 2007 |g 15(2021), 4 vom: 06. Apr., Seite 529-539 |w (DE-627)NLM204021901 |x 1876-4479 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2021 |g number:4 |g day:06 |g month:04 |g pages:529-539 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ecco-jcc/jjaa215 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2021 |e 4 |b 06 |c 04 |h 529-539 | ||